

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Not for submission under 37 CFR 1.99)	Application Number		10566112
	Filing Date		2006-01-24
	First Named Inventor	Chen, J.	
	Art Unit		
	Examiner Name		
	Attorney Docket Number	57637-1062	

U.S. PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	6200546	B1	2001-03-13	Hoffman et al.	
	2	6143274	A	2000-11-07	Tweedle et al.	
	3	6093382	A	2000-07-25	Wedeking et al.	
	4	6066309	A	2000-05-23	Zamora et al.	
	5	6027710	A	2000-02-22	Higashi et al.	
	6	5976495	A	1999-11-02	Pollak et al.	
	7	5886142	A	1999-03-23	Thakur et al.	
	8	5846519	A	1998-12-08	Tweedle et al.	

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10566112
Filing Date	2006-01-24
First Named Inventor	Chen, J.
Art Unit	
Examiner Name	
Attorney Docket Number	57637-1062

9	5780006	A	1998-07-14	Pollak et al.	
10	5720934	A	1998-02-24	Dean et al.	
11	5688487	A	1997-11-18	Linder et al.	
12	5665329	A	1997-09-09	Ramalingam et al.	
13	5662885	A	1997-09-02	Pollak et al.	
14	5656254	A	1997-08-12	Ramalingam et al.	
15	5608110	A	1997-03-04	Ramalingam et al.	
16	5474756	A	1995-12-12	Tweedle et al.	
17	5393512	A	1995-02-28	Vanderheyden et al.	
18	5387409	A	1995-02-07	Nunn et al.	
19	5384113	A	1995-01-24	Deutsch et al.	

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number		10566112
Filing Date		2006-01-24
First Named Inventor	Chen, J.	
Art Unit		
Examiner Name		
Attorney Docket Number	57637-1062	

20	5367080	A	1994-11-22	Toner et al.	
21	5364613	A	1994-11-15	Sieving et al.	
22	5262175	A	1993-11-16	Solanki	
23	5219556	A	1993-06-15	Wolfangel	
24	5183653	A	1993-02-02	Linder et al.	
25	5128119	A	1992-07-07	Griffiths	
26	5118797	A	1992-06-02	Jurisson et al.	
27	5075099	A	1991-12-24	Srinivasan et al.	
28	5053493	A	1991-10-01	Pak et al.	
29	5021556	A	1991-06-04	Srinivasan	
30	4075314	A	1978-02-21	Wolfangel et al.	

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10566112
Filing Date	2006-01-24
First Named Inventor	Chen, J.
Art Unit	
Examiner Name	
Attorney Docket Number	57637-1062

31	4963344	A	1990-10-16	Gries et al.	
32	4957939	A	1990-09-18	Gries et al.	
33	4935222	A	1990-06-19	Deutsch et al.	
34	4885363	A	1989-12-05	Tweedie et al.	
35	4808705	A	1989-02-28	Ferris	
36	4793987	A	1988-12-27	Henderson et al.	
37	4707353	A	1987-11-17	Bugaj et al.	
38	4652440	A	1987-03-24	Paik et al.	
39	4647447	A	1987-03-03	Gries et al.	
40	4645660	A	1987-02-24	Takahashi et al.	
41	4510125	A	1985-04-09	Grogg et al.	

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10566112
Filing Date	2006-01-24
First Named Inventor	Chen, J.
Art Unit	
Examiner Name	
Attorney Docket Number	57637-1062

42	4451451	A	1984-05-29	Rimmer	
43	4440738	A	1984-04-03	Fawzi et al.	
44	4416865	A	1983-11-22	Rhodes et al.	
45	4411881	A	1983-10-25	Tzodikov	
46	4390517	A	1983-06-28	O'Brien et al.	
47	4364920	A	1982-12-21	Winchell	
48	4232000	A	1980-11-04	Fawzi	

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

**U.S.PATENT APPLICATION PUBLICATIONS**

Remove

Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	20020054855		2002-05-09	Hoffman et al.	
	2	20040136906		2004-07-15	Cappelletti et al.	

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number		10566112
Filing Date		2006-01-24
First Named Inventor	Chen, J.	
Art Unit		
Examiner Name		
Attorney Docket Number		57637-1062

FOREIGN PATENT DOCUMENTS								Remove
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup> i	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
	1	93/22260	WO					<input type="checkbox"/>
	2	97/01520	WO					<input type="checkbox"/>
	3	2002/060491	WO					<input type="checkbox"/>
	4	2002/092005	WO					<input type="checkbox"/>
	5	2002/04030	WO					<input type="checkbox"/>
	6	2002/067859	WO					<input type="checkbox"/>
	7	1995/003280	WO					<input type="checkbox"/>
	8	1995/006633	WO					<input type="checkbox"/>
	9	1994/024853	WO					<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number		10566112
Filing Date		2006-01-24
First Named Inventor	Chen, J.	
Art Unit		
Examiner Name		
Attorney Docket Number	57637-1062	

10	98/16496	WO					<input type="checkbox"/>
11	86/06605	WO					<input type="checkbox"/>
12	91/03200	WO					<input type="checkbox"/>
13	95/28179	WO					<input type="checkbox"/>
14	96/23526	WO					<input type="checkbox"/>
15	97/36619	WO					<input type="checkbox"/>
16	1998/046612	WO					<input type="checkbox"/>
17	1999/017809	WO					<input type="checkbox"/>
18	1996/040756	WO					<input type="checkbox"/>
19	1991/001144	WO					<input type="checkbox"/>
20	2000/050086	WO					<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10566112
Filing Date	2006-01-24
First Named Inventor	Chen, J.
Art Unit	
Examiner Name	
Attorney Docket Number	57637-1062

If you wish to add additional Foreign Patent Document citation information please click the Add button			Add
<b>NON-PATENT LITERATURE DOCUMENTS</b>			Remove
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>5</sup>
	1	Garrison, W. M., "Reaction Mechanisms on the Radiolysis of Peptides, Polypeptides, and Proteins", Chem. Rev. 1987, 87, 381-398.	<input type="checkbox"/>
	2	Brechbiel MW, Gansow OA, "Backbone-substituted DTPA ligands for 90Y radioimmunotherapy", Bioconj. Chem. 1991; 2: 187-194.	<input type="checkbox"/>
	3	Liu and Edwards, "99mTc-Labeled Small Peptides as Diagnostic Radiopharmaceuticals", Chem Rev. 1999, 99, 2235-2268.	<input type="checkbox"/>
	4	Caravan et al., "Gadolinium(III) Chelates as MRI Contrast Agents: Structure, Dynamics, and Applications", Chem. Rev. 1999, 99, 2293-2352.	<input type="checkbox"/>
	5	Langer, M. et al., "99mTc-Labeled Neuropeptide Y Analogues as Potential Tumor Imaging Agents", Bioconjugate Chem. 2001, 12, 1028-1034.	<input type="checkbox"/>
	6	Mukai, H. et al. "G Protein Antagonists A novel hydrophobic peptide competes with receptor for G protein binding", Biol. Chem. 1992, 267, 16237-16243.	<input type="checkbox"/>
	7	Soil, R. et al. "Novel Analogues of Neuropeptide Y with a Preference for the Y1-receptor", Eur. J. Biochem. 2001, 268, 2828-2837.	<input type="checkbox"/>
	8	Langer, M. et al. "Novel Peptide Conjugates for Tumor-Specific Chemotherapy" J. Med. Chem. 2001, 44, 1341-1348.	<input type="checkbox"/>
	9	Kwekkreboom, D. et al. "Cholecystokinin Receptor Imaging Using an Octapeptide DTPA-CCK Analogue in Patients with Medullary Thyroid Carcinoma", Eur. J. Nucl Med. 200, 27, 1312-1317.	<input type="checkbox"/>



**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10566112
Filing Date	2006-01-24
First Named Inventor	Chen, J.
Art Unit	
Examiner Name	
Attorney Docket Number	57637-1062

10	Blok, D. et al. "Peptide Radiopharmaceuticals in Nuclear Medicine", Eur. J. Nucl Med. 1999, 26, 1511-1519.	<input type="checkbox"/>
11	Reubi, J. et al. "Co-expressed peptide receptors in breast cancer as a molecular basis for in vivo multireceptor tumour targeting" Eur. J. Nucl Med. 2002, 29, 655-662.	<input type="checkbox"/>
12	Heppeler A. et al. "Receptor targeting for tumor localisation and therapy with radiopeptides", Current Medicinal Chemistry (2000), 7(9), 971-994.	<input type="checkbox"/>
13	Li, W.P. et al. "Development of an in vitro model for assessing the in vivo stability of lanthanide chelates." Nucl. Med. Biol. 2001; 28(2): 145-154.	<input type="checkbox"/>
14	Siemion, I. Z. et al. "Anti-IL-1 Activity of Peptide Fragments of IL-1 Family Proteins", Peptides 1998, 19, 373-382.	<input type="checkbox"/>
15	McAfee, J. et al. "Radiolabeled Peptides and Other Ligands for Receptors Overexpressed in Tumor Cells for Imaging Neoplasms", Nuclear Medicine and Biology, 1996, 23, 673-676.	<input type="checkbox"/>
16	Parker, D. et al. "Implementation of macrocycle conjugated antibodies for tumor-targeting", Pure and Applied Chemistry (1989), 61(9), 1637-41.	<input type="checkbox"/>
17	Schubiger, P. et al. "Vehicles, Chelators, and Radionuclides: Choosing the "Building Blocks" of an Effective Therapeutic Radioimmunoconjugate", Bioconjugate Chemistry (1996), 7(2), 165-79.	<input type="checkbox"/>
18	Cai, R. et al. "Potent bombesin antagonists with C-terminal Leu- (CH <sub>2</sub> -N)-Tyr-NH <sub>2</sub> or its derivatives", Proceedings of the National Academy of Sciences of the United States of America (1994), 91(26), 12664-8	<input type="checkbox"/>
19	Moody, Terry W. "Peptides and growth factors in non-small cell lung cancer", Peptides (Tarrytown, New York) (1996), 17(3), 545-555	<input type="checkbox"/>
20	Wilbur, D. Scott. "Radiohalogenation of proteins: An overview of radionuclides, labeling methods and reagents for conjugate labeling", Bioconjugate Chemistry (1992), 3(6), 432-70.	<input type="checkbox"/>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10566112
Filing Date	2006-01-24
First Named Inventor	Chen, J.
Art Unit	
Examiner Name	
Attorney Docket Number	57637-1062

21	Bolin, D. et al. "Comparison of Cyclic and Linear Analogs of Vasoactive Intestinal Peptide", Peptides: Chemistry, Structure and Biology, Mayflower Scientific LTD., 1996, pgs 174-175.	<input type="checkbox"/>
22	Kim S. H. et al. "Potent Somatostatin Analogs Containing N-terminal Modifications" Peptides: Chemistry, Structure and Biology, Mayflower Scientific LTD., 1996, pgs 241-243.	<input type="checkbox"/>
23	Brian, G. et al. "Structure-Activity Relationship Studies of New Backbone-cyclic Substance P Analogs" Peptides: Chemistry, Mayflower Scientific LTD., 1996, pgs 697-698.	<input type="checkbox"/>
24	Coy, D. H. et al. "Probing Peptide Backbone Function in Bpmbsin" J. Biol. Chem., 1988, 263, pp. 5056-60.	<input type="checkbox"/>
25	Leban, J. et al. "Structure-activity relationship study on GRP antagonists having a C-terminal DPro (CH <sub>2</sub> NH)Phe-NH <sub>2</sub> " Pept.: Chem., Struct. Biol., Proc. Am. Pept. Symp., 13th (1994), Meeting Date 1993, 417-19.	<input type="checkbox"/>
26	Fischman, A. et al. "A ticket to ride: peptide radiopharmaceuticals" Journal of Nuclear Medicine (1993), 34(12), 2253-63.	<input type="checkbox"/>
27	Lister-James, et al. "Pharmacokinetic considerations in the development of peptide-based imaging agents", The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR) (1997), 41(2), 111-8.	<input type="checkbox"/>
28	Qin, Y et al. "Bombesin antagonists inhibit in vitro and in vivo growth of human gastric cancer and binding of bombesin to its receptors", Journal of Cancer Research and Clinical Oncology (1994), 120(9), 519-28.	<input type="checkbox"/>
29	Eckelman, W. "Radiolabeling with technetium-99m to study high-capacity and low-capacity biochemical systems", European Journal of Nuclear Medicine (1995), 22(3), 249-63.	<input type="checkbox"/>
30	Krenning, E. et al "Essentials of peptide receptor scintigraphy with emphasis on the somatostatin analog octreotide", Seminars in Oncology (1994), 21(5, Suppl. 13), 6-14.	<input type="checkbox"/>
31	Davis T. et al. "Metabolic stability and tumor inhibition of bombesin/GRP receptor antagonist." Peptides, 1992, 13, 401-407	<input type="checkbox"/>

# **INFORMATION DISCLOSURE STATEMENT BY APPLICANT** ( Not for submission under 37 CFR 1.99)

Application Number		10566112
Filing Date		2006-01-24
First Named Inventor	Chen, J.	
Art Unit		
Examiner Name		
Attorney Docket Number	57637-1062	

32	Fritzberg, A. et al. "Molecular targeting chemistry in rationale drug design", Chem. Struct. Approaches Ration. Drug Des. (1995), 125-58.	<input type="checkbox"/>
33	Jensen R. et al. "Bombesin receptor antagonists: different classes and cellular basis of action", Recent results in cancer research. (1993), 129, 87-113.	<input type="checkbox"/>
34	Kasokat T et al. "Quantification of dechelation of gadopentetate dimeglumine in rats." Diagnostic A/ds, 1992; 42(6): 869-76.	<input type="checkbox"/>
35	Cutler C. et al. "Current and potential therapeutic uses of lanthanide radioisotopes." Cancer Biother. Radiopharm. 2000; 15(6).	<input type="checkbox"/>
36	Reubi et al. "The Role of Peptides and Their Receptors as Tumor Markers" Gastrointestinal Hormones in Medicine, Vol. 22, No. 4, pg. 899-939.	<input type="checkbox"/>
37	Budsky, et al. "Preparation methods for bifunctional chelates for conjugation with antibodies" Radioisotopy (1990), 31(4), 70-80)).	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

## **EXAMINER SIGNATURE**

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> See Kind Codes of USPTO Patent Documents at [www.USPTO.GOV](http://www.USPTO.GOV) or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10566112
Filing Date	2006-01-24
First Named Inventor	Chen, J.
Art Unit	
Examiner Name	
Attorney Docket Number	57637-1062

**CERTIFICATION STATEMENT**

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

**OR**

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

- ☐ See attached certification statement.
- ☐ Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- ☒ None

**SIGNATURE**

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Albert B. Chen/	Date (YYYY-MM-DD)	2007-03-27
Name/Print	Albert B. Chen	Registration Number	41,667

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

## Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.